肿瘤坏死因子-α-238基因多态性与肿瘤化疗后乙型肝炎病毒再激活的关系

Correlation between TNF-α-238 gene polymorphism and hepatitis B virus reactivation in patients with malignant tumors after chemotherapy

目的探讨肿瘤坏死因子（TNF）-α-238基因多态性与肿瘤患者化疗后乙型肝炎病毒（HBV）再激活的关系。方法采用聚合酶联反应一限制性片断长度多态性（PCR—RFLP）分析法检测100例携带HBV的肿瘤患者TNF-α基因启动子TNFn238的多态性；对HBV感染者检测化疗前和化疗后HBV—DNA水平，HBV-DNA水平增加不低于10倍或绝对值达到1×10^9拷贝／ml视为再激活。结果化疗后HBV—DNA定量[（3．02±0．68）logcopies／ml}较化疗前[（2．49±0．23）logcopies／ml}高（t=-7．383，p=0．000）；携带HBV的肿瘤患者接受化疗后，HBV再激活组22例G／A所占比例（27．3％，6／22）明显高于未激活组78例G／A所占比例（3．8％，3／78）（x2=11．499，P=0．001）。结论携带HBV的肿瘤患者化疗后HBV再激活与TNF-α-238基因型的多态性有关。

Objective To investigate the correlation between the single nueleotide polymorphism （SNP） of tumor necrosis factor （TNF-α） gent promotor-238 and hepatitis B virus （HBV） reactivation in patients with malignant tumors after chemotherapy. Methods Po!ymerase chain reaction restriction fragment length polymorphism assay （PCR-RFLP） was used to detect the SNP at TNF-α 238 site among 100 malignant tumor patients with HBV infection. HBV-DNA levels in patients were detected before and after chemotherapy-α-IBV reactivation was defined as that HBV DNA level greater than 10 fold increase compared with loefore chemotherapy or higher than 1 ×109 logeoples/ml. Results The quantification of LIBV-DNA was higher after chemotherapy than before chemotherapy （（3.02± 0.6g） logeopies/ml ws. （2.49±6.23） logeopies/ml, t=-7. 383, P=0. 0001. Among the patients with malignant tumor and HBV infection, the genotype frequency of G/A was higher in HBV reactivation group than in non reactivation group after chemotherapy （27.3% （6/22） vs 3.8%（3/ 78）,x2= 11. 499, P=0. 0011. Conclusions HBV reactivation is associated with TNFa 238 gent polymorphism in malignant tumor patients with HBV infection after chemotherapy.